ORIGINAL ARTICLE The abstract was presented at the 2022 annual meeting of the American Society for Radiation Oncology. Abstract Background This study was aimed at developing and validating a decision-making tool predictive of overall survival (OS) for patients receiving stereotactic body radiation therapy (SBRT) for spinal metastases. Methods Three hundred sixty-one patients at one institution were used for the training set, and 182 at a second institution were used for external validation.
